FoRx Therapeutics AG
FoRx Therapeutics AG develops innovative small molecule therapeutics that target DNA Damage Response (DDR) pathways for anti-cancer therapy. The company's pipeline encompasses novel, first-in-class as well as differentiated, best-in-class programs for oncology indications. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which is currently in final IND-enabling studies and slated to enter the clinic in July 2025.
Date, time and room information
May 6, 13:00 - 13:15, room Montreal
Category
Clinical stage development company
Title of the presentation
FORX-428: A novel and highly potent PARG inhibitor with best-in-class potential on the way to the clinic
Speaker information
| Name | Position | Institution |
|---|---|---|
| Tarig Bashir | CEO | FoRx Therapeutics AG |
